- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Rationale:
- The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due to it not meeting the eligibility criteria for selection as an antifungal as per section 3.8 of the prioritisation manual.
- ID number:
- 12165
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
Related links
For further information on how we select topics for development, please see our page about topic prioritisation